Ver el código de «Template:Sulfonylurea Toxicity»

===Hypoglycemia from [[Sulfonylurea toxicity|Sulfonylureas]]<ref>Rowden AK, Fasano CJ. Emergency management of oral hypoglycemic drug toxicity. Emerg Med
Clin N Am 2007; 25:347-356</ref><ref>Howland MA. Antidotes in Depth: Octreotide. In: Flomenbaum NE, Goldfrank LR, Hoffman RS et al,
eds: Goldfrank’s Toxicologic Emergencies. New York NY, 2006;770-773</ref>===

====[[Activated charcoal]]<ref>Tran D et al. Oral Hypoglycemic Agent Toxicity Treatment & Management. Jul 14, 2015. http://emedicine.medscape.com/article/1010629-treatment#showall.</ref>====
*Administer activated charcoal, preferably within 1 hr of ingestion
*Multiple doses may be beneficial, especially for glipizide

====Glucose Treatment====
*Initial Therapy regardless of known cause

;Adults: 
*50mL [[D50W]] bolus
*Start a D10 1/2NS drip  (100mL/hr)

;Children: 
*1mL/kg of D50W OR
* 2mL/kg D25W OR 5-10mL/kg D10W
*Neonate: 5-10 mL/kg D10W

====[[Octreotide]]<ref>Fasano CJ et al. Comparison of Octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008; 51:400-406</ref>====
*Theoretical benefit to reduce risk of recurrent hypoglycemia
*Hyperpolarization of the beta cell results in inhibition of Ca influx and prevents insulin release
*50-100 mcg subcutaneous in adults with repeat dosing Q6hrs
*2 mcg/kg (max 150mcg) subcutaneously should be used in children
*Continuous infusion of 50-125 mcg/hr is an alternative in adults

====Special Considerations====
*Caution in using [[glucagon]] drip
**[[Glucagon]] also has an insulin-releasing effect
**May subsequently cause initial paradoxical hypoglycemia